Holen Sie sich die Stockscreener-App
21.16
15.12%
2.635
Schlusskurs vom Vortag:
$18.52
Offen:
$19.9
24-Stunden-Volumen:
29.08M
Relative Volume:
5.69
Marktkapitalisierung:
$3.53B
Einnahmen:
$93.95M
Nettoeinkommen (Verlust:
$-129.87M
KGV:
-23.51
EPS:
-0.9
Netto-Cashflow:
$-202.88M
1W Leistung:
+205.01%
1M Leistung:
+171.25%
6M Leistung:
+202.41%
1J Leistung:
+40.63%
1-Tages-Spanne:
$17.90
$21.73
1-Wochen-Bereich:
$6.93
$21.73
52-Wochen-Spanne:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Vergleichen Sie WVE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
21.09 | 3.10B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.55 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.37 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.50 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.54 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.04 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
WVE: Wells Fargo Raises Price Target with Overweight Rating | WV - GuruFocus
Wave Life Sciences: Stock Skyrockets on Positive Phase 1 Clinical Trial Results - StocksToTrade
Wave Surges As Obesity Candidate Cuts Fat And Spares Muscle - Citeline News & Insights
Wave Life Sciences (WVE) Upgraded to Outperform on Promising Obe - GuruFocus
Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007 (WVE:NASDAQ) - Seeking Alpha
Wave Life Sciences (WVE): Revisiting Valuation After a 39% YTD Surge and 3-Year Share Price Tripling - simplywall.st
Cantor Fitzgerald Raises Price Target for WVE to $34.00 | WVE St - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active - Markets Financial Content
WVE: Clear Street Raises Price Target and Maintains Buy Rating | WVE Stock News - GuruFocus
RBC Capital Upgrades WVE with a 200% Price Target Increase | WVE Stock News - GuruFocus
WAVE Life Sciences stock price target raised to $40 from $19 at Canaccord - Investing.com
JPMorgan Chase & Co. Boosts Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
Raymond James raises WAVE Life Sciences stock price target to $21 on obesity drug data - Investing.com
WAVE Life Sciences (NASDAQ:WVE) Sets New 52-Week HighHere's Why - MarketBeat
Wave Life Sciences (WVE) Stock Reaches 52-Week High on Positive Obesity Trial Data - CoinCentral
WAVE Life Sciences (NASDAQ:WVE) Nasdaq Composite ETF Biotech Trends - Kalkine Media
RBC Capital upgrades WAVE Life Sciences stock to Outperform on obesity drug data - Investing.com Australia
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday - sharewise.com
Wave Life Sciences Rides Positive Data To Big Stock Gains - Finimize
Wave Life Sciences Soars 147% on Breakthrough “Targeted Fat Loss” Drug Data - NAI500
Nvidia, AMD, Wave Life Sciences, Toll Brothers And Carvana: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open - ts2.tech
Wave Life Sciences announces $250M public offering and pre-funded warrants - MSN
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday - The Motley Fool
Wave (WVE) Shows Promising Phase 1 Results in Obesity Study - GuruFocus
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Insider Monkey
Wave Life Sciences (WVE) Launches $250 Million Public Offering - GuruFocus
Wave Life Sciences Launches $250 Million Stock, Warrant Offering - marketscreener.com
Wave Life Sciences (WVE) Stock: Holds Steady as WVE-007 Shows Promising Obesity Treatment Results - parameter.io
Wave Life Sciences announces $250 million public offering - Investing.com
Wave Life Sciences Explodes Higher On Preliminary WVE-007 Body Composition Results (NASDAQ:WVE) - Seeking Alpha
Wave Life Sciences (Nasdaq: WVE) begins $250M share and pre-funded warrant sale - Stock Titan
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
Wave Life skyrockets on obesity drug trial, Strategy buys bitcoin - Yahoo Finance
Raymond James raises Wave Life Sciences stock price target to $21 - Investing.com Nigeria
Wave Life Sciences’ WVE-007: Promising Data and Safety Profile Elevate Buy Rating and Price Target - TipRanks
WVE Stocks on the Rise: Key Insights - StocksToTrade
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Leerink Partners raises WAVE Life Sciences stock price target to $28 on promising results - Investing.com
Wave Life Sciences (WVE): Assessing Valuation After Recent Share Price Weakness and Long-Term Gains - Yahoo Finance
Why Is Wave Life Sciences Stock Skyrocketing Monday?WAVE Life Sciences (NASDAQ:WVE) - Benzinga
Wave Life Sciences Stock (WVE) Soars 135% on Obesity Drug Results - TipRanks
Wave Life Sciences (WVE) Stock Surges as Obesity Drug Shows Promising Fat Loss Results - parameter.io
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpWhat's Next? - MarketBeat
Stocks making the biggest moves midday: Paramount Skydance, Wave Lifesciences, Confluent & more - CNBC
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Wave Life Sciences Shares Rise After Phase 1 Interim Data on Obesity Drug Candidate - marketscreener.com
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th - Yahoo Finance
Wave Life, Structure and Ascletis post wins in obesity management - BioWorld MedTech
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):